... recently pub-lished in HAE prophylaxis and therapy and these haveled to the licensing of pdC1INH (Berinert®,CSLBehr-ing; Cinryze®, ViroP harma; Ceto r-n®, Sanquin) in manyparts of the ... C1 INHIBITOR (C1INH) If “failing” on demand therapy with any of the angioedema event therapies (AERx’s; pdC1INH, rhC1INH, bradykinin B2 receptor antagonist, kallikrein inhibibitor): Then ... administration of intervention therapy(such as infusion of pdC1INH, rhC1INH, bradykinin B2rec eptor antagonist, or kallikrein inhibitor). It is recom-mended that patients carry two doses of...